ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "psoriasis"

  • Abstract Number: 136 • 2020 Pediatric Rheumatology Symposium

    Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center

    Sarah Kodama1, Deepti Gupta 2, Erin Sullivan 3 and Yongdong Zhao 4, 1School of Medicine, Virginia Commonwealth University, Richmond, 2Pediatric Dermatology, School of Medicine, University of Washington, Seattle, 3Seattle Children's Research Institute, Seattle, 4University of Washington, Seattle

    Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are…
  • Abstract Number: L01 • 2019 ACR/ARP Annual Meeting

    Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study

    Yinzhu Jin 1, Hemin Lee 1, Moa Lee 2, Joan Landon 3, Joseph Merola 4, Rishi Desai 5 and Seoyoung C. Kim1, 1Brigham and Women's Hospital and Harvard Medical School, Boston, 2University of North Carolina Chapel Hill, Chapel Hill, North Carolina, 3Brigham and Women's Hospital, Boston, Massachusetts, 4Harvard Medical School, Brigham and Women's Hospital, Boston, 5Brigham and Women's hospital, Boston

    Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
  • Abstract Number: 823 • 2019 ACR/ARP Annual Meeting

    The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study

    Lingyi Li1, Na Lu 1, Eric Sayre 1, Hui Xie 2, Diane Lacaille 3, John Esdaile 4 and J. Antonio Avina-Zubieta 5, 1Arthritis Research Canada, Vancouver, BC, Canada, 2Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, 3Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, 4Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, 5Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) is associated with increased morbidity and mortality. Previous studies have shown…
  • Abstract Number: 2463 • 2019 ACR/ARP Annual Meeting

    Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis

    Eric Toussirot1, Francois Aubin 1, maxime Desmarets 1, Daniel WENDLING 2, benoit Augé 3, jerome Gillard 4, olivier messica 4, Xavier Guillot 1, caroline Laheurte 5, elisabeth monnet 1 and gilles dumoulin 1, 1University Hospital, Besancon, France, 2Rheumatology, University Teaching Hospital (CHRU), Besançon, France, 3private office, besancon, France, 4Centre Hospitalier, Lons le Saunier, France, 5EFS, besancon, France

    Background/Purpose: Obesity is a leading comorbidity in both psoriasis (Pso) and psoriatic arthritis (PsA) and is associated with common metabolic complications and increased cardiovascular (CV)…
  • Abstract Number: 1008 • 2019 ACR/ARP Annual Meeting

    C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility

    Fatima Abji1, Anastasiya Muntyanu 2, Remy Pollock 1, Rohan Machhar 1, Justine (Yang) Ye 3, Vinod Chandran 4 and Dafna Gladman 5, 1Krembil Research Institute, University Health Network, Toronto, Canada, 2University of Toronto, University Health Network, Toronto, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada, 4University Health Network, University of Toronto, Toronto, Canada, 5Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada

    Background/Purpose: We previously identified CXCL10, NOTCH2NL, HAT1, and SETD2 as differentially expressed between psoriasis arthritis (PsA) and psoriasis patients without arthritis (PsC). This study aimed…
  • Abstract Number: 2481 • 2019 ACR/ARP Annual Meeting

    Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center

    Iñigo Gonzalez-Mazon1, Lara Sanchez-Bilbao 2, Natalia Palmou-Fontana 1, DAVID MARTINEZ-LOPEZ 3, Mónica Calderón-Goercke 4, DIANA PRIETO- PENA 1, Susana Armesto-Alonso 3, Miguel A Gonzalez-Gay 2 and Ricardo Blanco 2, 1Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 2Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 4Hospital Marqués de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Uveitis is an extra articular manifestation of psoriatic arthritis (PsA). Uveitis may be more chronic Biological therapy, especially monoclonal TNF inhibitors, are useful to…
  • Abstract Number: 1011 • 2019 ACR/ARP Annual Meeting

    Single Cell RNA Sequencing of Patients with Psoriatic Disease

    Rohan Machhar1, Kun Liang 2, Remy Pollock 1 and Dafna Gladman 3, 1Krembil Research Institute, University Health Network, Toronto, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3Krembil Research Institute, U of Toronto, Toronto, ON, Canada

    Background/Purpose: Delayed diagnosis of psoriatic arthritis (PsA) can lead to poor clinical outcomes. A large proportion of PsA patients remain undiagnosed due to a lack…
  • Abstract Number: 2485 • 2019 ACR/ARP Annual Meeting

    Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy

    Angela Gupta1, Sofi Damjanovska 2, David Zidar 3, Donald Anthony 4 and Maya Mattar 3, 1Case Western Reserve University, Cleveland, 2Case Western Reserve University, Cleveland Heights, OH, 3Louis Stokes Cleveland VA Medical Center, Cleveland, OH, 4Case Western Reserve University, Cleveland, OH

    Background/Purpose: Red blood cell distribution width (RDW) is a parameter that measures variation in red blood cell size and volume. It is elevated when there…
  • Abstract Number: 1096 • 2019 ACR/ARP Annual Meeting

    Learning the Relationships Between Psoriatic Arthritis and a Patient’s History of Musculoskeletal Symptoms from Electronic Health Records Using Bayesian Networks

    Amelia Green 1, Theresa Smith 1 and Neil McHugh1, 1University of Bath, Bath, England, United Kingdom

    Background/Purpose: Electronic health records (EHRs) from large health care systems provide access to rich and comprehensive patient-specific information from many sources consisting of heterogeneous data…
  • Abstract Number: 2490 • 2019 ACR/ARP Annual Meeting

    The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype

    Meital Yerushalmi1, Osvaldo Espin-Garcia 2, Justine (Yang) Ye 3, Remy Pollock 4, Sara Rahmati 3, Lihi Eder 5, Mark Silverberg 6 and Vinod Chandran 7, 1University of Toronto, University Health Network, Toronto, ON, Canada, 2Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada, 4Krembil Research Institute, University Health Network, Toronto, Canada, 5Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, 6Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 7University Health Network, University of Toronto, Toronto, Canada

    Background/Purpose: Psoriasis is an inflammatory skin disease. Psoriatic arthritis (PsA) is an inflammatory arthritis that affects 30% of psoriasis patients. The heterogeneity of psoriatic disease…
  • Abstract Number: 1520 • 2019 ACR/ARP Annual Meeting

    Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status

    Steven Feldman 1, Jingchuan Zhang2, Diane Martinez 3, Lorena Lopez-Gonzalez 3, Elizabeth Holt Marchlewicz 3, George Shrady 3, Alan Mendelsohn 4 and Yang zhao 5, 1Wake Forest Baptist Health, Winston-Salem, NC, 2Sun Pharmaceutical Industries, Princeton, NJ, 3IBM Watson Health, Washington, DC, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 5Sun Pharmaceutical Industries, Princeton

    Background/Purpose: Long-term real-world treatment patterns of psoriasis patients are not well characterized, especially those with comorbid psoriatic arthritis (PsA). This study examined the treatment patterns…
  • Abstract Number: 2499 • 2019 ACR/ARP Annual Meeting

    Predicting Risk of Developing Psoriatic Arthritis (PsA) in Siblings of Patients with Psoriatic Arthritis

    Winifred Badaiki1, Quan Li 2, Tanya Burry 1, Fiona Landells 1, Rachel Gehue 1, Cindy Penney 3, DIanne Codner 1, Amanda Dohey 1, Kerri Smith 1, Fatima Abji 4, Dafna Gladman 5, Darren O'Rielly 1, Vinod Chandran 6 and Proton Rahman 7, 1Memorial University, St. Johns, Canada, 2Toronto Western Hospital, Toronto, Canada, 3Memorial University, St Johns, Canada, 4Memorial University, Toronto, Canada, 5Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 6University Health Network, University of Toronto, Toronto, Canada, 7Memorial University, St. Johns, NL, Canada

    Background/Purpose: Delay in diagnosis of psoriatic arthritis (PsA) has been shown to contribute to poor radiographic and functional outcome and less successful response to treatment…
  • Abstract Number: 1523 • 2019 ACR/ARP Annual Meeting

    Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis

    Alan Menter 1, Zoe Draelos 2, Jayme Heim 3, Jeff Parno 4, Alan Mendelsohn4, Stephen Rozzo 4 and Christopher Griffiths 5, 1Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX, USA, Dallas, TX, 2Dermatology Consulting Services, High Point, NC, USA, High Point, NC, 3West Michigan Dermatology, Holland, MI, USA, Holland, MI, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 5Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom

    Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody approved for the treatment of moderate-to-severe chronic plaque psoriasis. An inverse efficacy–body weight relationship has been…
  • Abstract Number: 2502 • 2019 ACR/ARP Annual Meeting

    Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study

    Jennifer Belasco1, Sandra Garcet 1, Mustimbo roberts 2, Judilyn Fuentes-Duculan 1, Norma Kunjravia 1, Inna Cueto 1, Israel Coats 1, Xuan Li 1, Philip Mease 3, Alice Gottlieb 4, Oliver FitzGerald 5 and James Krueger 1, 1The Rockefeller University, New York, NY, 2Bristol-Myers Squibb, Princeton, NJ, 3Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 4Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, 5University College Dublin, Dublin, Ireland

    Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulation modulator, has been shown to improve disease activity in patients with psoriatic arthritis (PsA), but its effect on…
  • Abstract Number: 1526 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study

    Wendy Cantrell 1, Patricia Lee 2, Emil Tanghetti 3, Alan Mendelsohn4, Jeff Parno 4, Stephen Rozzo 4 and Wilson Liao 5, 1Department of Dermatology, University of Alabama Birmingham, Birmingham, AL, USA; Dermatology at the Whitaker Clinic, Birmingham, AL, USA, Birmingham, AL, 2Center for Clinical Studies, Webster, TX, USA, Webster, TX, 3Center for Dermatology and Laser Surgery, Sacramento, CA, USA, Sacramento, CA, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 5Department of Dermatology, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA

    Background/Purpose: We assessed residual plaque psoriasis in patients successfully treated with anti–interleukin-23p19 monoclonal antibody tildrakizumab (TIL) who interrupted treatment, relapsed, and were retreated vs continuously…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.